Head-to-head · WeighScore
Harbor vs Lavender Sky Health
The verdict
Harbor takes it — 72/100 to 68.7/100.
Harbor grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Harbor is a physician-led telehealth platform offering compounded semaglutide (from $99/mo) and compounded tirzepatide (from $149/mo) — among the lowest headline prices in the market.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Harbor | Lavender Sky Health |
|---|---|---|
| WeighScore | 72/100 | 68.7/100 |
| Grade | C | C |
| Scorecard rank | #86 | #138 |
| Semaglutide | $99/mo (starting dose, compounded) | $139/mo (starting dose, month to month, Southend Pharmacy, compounded) |
| Tirzepatide | $149/mo (starting dose, compounded) | $149/mo (starting dose, month to month, ReviveRx, compounded) |
| Coverage | Coverage not published | All 50 states |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Injection only |
Graded #86 · C
Strengths
- Compounded semaglutide from $99/mo and tirzepatide from $149/mo — among the lowest headline prices in the market
- LegitScript certified with 4.7-star rating, 94.6% success rate, and 10,000+ verified members
- 24/7 physician access with ongoing consultations, dosage adjustments, and free discreet shipping
- 12-Month Money Back Guarantee if you don't reach your weight-loss goal
- HSA/FSA eligible; no hidden fees, no insurance billed
Where it loses points
- Compounded medications are not FDA-approved; compounding pharmacy names not publicly disclosed
- Dietitian support offered only post-program (maintenance phase), not during active treatment
- State-specific consultation types vary; nationwide availability unconfirmed for all states
- No labs disclosed; patient portal is a third-party platform (mdintegrations), not native
- Newer brand; success rate and member counts are on-site claims, not third-party verified
Graded #138 · C
Strengths
- The treatment-plan pricing page publishes every pharmacy's full ladder rather than one headline figure, so the cheaper prepaid tiers are visible alongside the monthly ones
- A genuine month-to-month starter plan exists with no prepay, and the cheapest of them is what is filed above — Southend for semaglutide, ReviveRx for tirzepatide
- Compounded plans include the price of the medication, and shipping and supplies are stated as included
- Both semaglutide and tirzepatide are offered, across roughly ten named compounding pharmacies
Where it loses points
- This is a marketplace, not one price: every figure belongs to a named pharmacy on a named plan, and the pharmacy and plan have to travel with the number for it to mean anything
- Most of the ladder is prepaid — Tier plans need 8-10 weeks up front and Extended plans 3-4 months — and only a handful of the pharmacies publish a month-to-month starter plan at all
- Brand-name plans add a separate $25 monthly treatment-plan fee and explicitly do not include the price of the medication; only the compounded plans include it
- No price appears on the homepage, and the pricing page is the only place the ladders are published
- Compounded semaglutide and tirzepatide are not FDA-approved finished products
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.